MARSEILLES, France, Jan. 31, 2008--Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announces that its partnership with Novo Nordisk A/S is being refocused to the inflammatory field. This follows today’s announcement by Novo Nordisk A/S of its commitment to inflammatory diseases and exit of oncology in 2008.
